Opens in a new tab
weight loss drugs risk
November 10, 2026

Weight Loss Drugs May Carry Eye-Stroke Risk; Read This

By Drew Hayes

The GLP-1 weight loss drugs are all the rage, giving weight reducing relief to many–but there are risks.

The FDA is issuing a new warning about popular weight-loss and diabetes medications, including Ozempic, Wegovy, Mounjaro, and Zepbound. The FDA emphasizes the risk remains rare, and a direct cause-and-effect relationship has not been established.

Federal regulators are requiring new safety labels warning of a potentially increased risk of a rare but serious eye condition that can cause permanent vision loss.

The condition, sometimes called an eye stroke, occurs when blood flow to the optic nerve is reduced, potentially causing sudden, painless blindness in one eye.

You make the call about the risk/reward: In a review of more than 134,000 patients, the FDA found about 6 cases of the rare eye condition annually for every 100,000  patients taking GLP-1 drugs, compared with about four among patients receiving other treatments or placebos. This is a new FDA-required safety warning, not a recall or a declaration that the drugs are unsafe for everyone.

Patients experiencing sudden vision changes should seek immediate medical attention. As always, you should consult with your doctor and thoroughly research any medication before taking it.

AI helped prepare this story

About the Author

Drew Hayes
Chief Content Officer